SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '2b4c'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1NV8_A_SAMA300_0 (HEMK PROTEIN)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	6 / 12	PHE H 96 ILE H 52 GLY H 100 GLY H 100 PHE H 54 PRO H 98	None	1.36A	1nv8A-2b4cH: undetectable	1nv8A-2b4cH: 19.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1NV8_B_SAMB301_0 (HEMK PROTEIN)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	6 / 12	PHE H 96 ILE H 52 GLY H 100 GLY H 100 PHE H 54 PRO H 98	None	1.33A	1nv8B-2b4cH: undetectable	1nv8B-2b4cH: 19.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1VQ1_B_SAMB301_0 (N5-GLUTAMINE METHYLTRANSFERASE, HEMK)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	6 / 12	PHE H 96 ILE H 52 GLY H 100 GLY H 100 PHE H 54 PRO H 98	None	1.36A	1vq1B-2b4cH: undetectable	1vq1B-2b4cH: 18.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FQY_A_ADNA400_1 (MEMBRANE LIPOPROTEIN TMPC)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	ASP H 86 PHE H 63 MET H 80 PHE H 69 GLY H 65	None	1.15A	2fqyA-2b4cH: undetectable	2fqyA-2b4cH: 22.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HUO_A_PNNA302_0 (CTX-M-9 EXTENDED-SPECTRUM BETA-LACTAMASE)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	4 / 6	LEU H 189 GLY H 190 ALA H 125 PRO H 126	None	0.45A	3huoA-2b4cH: undetectable	3huoA-2b4cH: 22.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVN_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.90A	4qvnH-2b4cH: undetectable 4qvnI-2b4cH: undetectable	4qvnH-2b4cH: 20.72 4qvnI-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVN_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 10	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.90A	4qvnV-2b4cH: undetectable 4qvnW-2b4cH: undetectable	4qvnV-2b4cH: 20.72 4qvnW-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVP_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.87A	4qvpH-2b4cH: undetectable 4qvpI-2b4cH: undetectable	4qvpH-2b4cH: 20.72 4qvpI-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVP_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.87A	4qvpV-2b4cH: undetectable 4qvpW-2b4cH: undetectable	4qvpV-2b4cH: 20.72 4qvpW-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVQ_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.89A	4qvqH-2b4cH: undetectable 4qvqI-2b4cH: undetectable	4qvqH-2b4cH: 20.72 4qvqI-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVQ_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	4qvqV-2b4cH: undetectable 4qvqW-2b4cH: undetectable	4qvqV-2b4cH: 20.72 4qvqW-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVV_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.92A	4qvvH-2b4cH: undetectable	4qvvH-2b4cH: 20.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVV_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.92A	4qvvV-2b4cH: undetectable	4qvvV-2b4cH: 20.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVY_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.92A	4qvyH-2b4cH: undetectable	4qvyH-2b4cH: 20.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVY_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.93A	4qvyV-2b4cH: undetectable 4qvyW-2b4cH: undetectable	4qvyV-2b4cH: 20.72 4qvyW-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW0_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.91A	4qw0H-2b4cH: undetectable 4qw0I-2b4cH: undetectable	4qw0H-2b4cH: 20.72 4qw0I-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW0_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.91A	4qw0V-2b4cH: undetectable 4qw0W-2b4cH: undetectable	4qw0V-2b4cH: 20.72 4qw0W-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW1_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.92A	4qw1H-2b4cH: undetectable 4qw1I-2b4cH: undetectable	4qw1H-2b4cH: 20.72 4qw1I-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW1_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.92A	4qw1V-2b4cH: undetectable 4qw1W-2b4cH: undetectable	4qw1V-2b4cH: 20.72 4qw1W-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QWU_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.92A	4qwuH-2b4cH: undetectable 4qwuI-2b4cH: undetectable	4qwuH-2b4cH: 20.72 4qwuI-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QWU_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.93A	4qwuV-2b4cH: undetectable 4qwuW-2b4cH: undetectable	4qwuV-2b4cH: 20.72 4qwuW-2b4cH: 21.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ALC_L_TIQL1210_1 (ANTI-TICAGRELOR FAB 72, HEAVY CHAIN ANTI-TICAGRELOR FAB 72, LIGHT CHAIN)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 9	TRP H 47 ILE H 52 THR H 56 TYR H 100 ASP H 95	None	1.40A	5alcH-2b4cH: 27.8	5alcH-2b4cH: 80.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BXN_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.92A	5bxnH-2b4cH: undetectable 5bxnI-2b4cH: undetectable	5bxnH-2b4cH: 20.72 5bxnI-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CZ7_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.89A	5cz7V-2b4cH: undetectable 5cz7W-2b4cH: undetectable	5cz7V-2b4cH: 20.72 5cz7W-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5D0X_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.90A	5d0xV-2b4cH: undetectable	5d0xV-2b4cH: 20.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L5F_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.87A	5l5fH-2b4cH: undetectable 5l5fI-2b4cH: undetectable	5l5fH-2b4cH: 20.72 5l5fI-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L5F_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	5l5fV-2b4cH: undetectable 5l5fW-2b4cH: undetectable	5l5fV-2b4cH: 20.72 5l5fW-2b4cH: 21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HWD_H_BO2H301_0 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	1.05A	6hwdH-2b4cH: undetectable 6hwdI-2b4cH: undetectable	6hwdH-2b4cH: 17.31 6hwdI-2b4cH: 14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HWD_V_BO2V301_0 (PROTEASOME SUBUNIT BETA TYPE-2)	2b4c	ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	1.05A	6hwdV-2b4cH: undetectable	6hwdV-2b4cH: 17.31

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1NV8_A_SAMA300_0","HEMK PROTEIN","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",6,"PHE H  96;ILE H  52;GLY H 100;GLY H 100;PHE H  54;PRO H  98","None","1.36A","1nv8A-2b4cH:undetectable","1nv8A-2b4cH:19.58"],["1NV8_B_SAMB301_0","HEMK PROTEIN","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",6,"PHE H  96;ILE H  52;GLY H 100;GLY H 100;PHE H  54;PRO H  98","None","1.33A","1nv8B-2b4cH:undetectable","1nv8B-2b4cH:19.58"],["1VQ1_B_SAMB301_0","N5-GLUTAMINE METHYLTRANSFERASE, HEMK","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",6,"PHE H  96;ILE H  52;GLY H 100;GLY H 100;PHE H  54;PRO H  98","None","1.36A","1vq1B-2b4cH:undetectable","1vq1B-2b4cH:18.92"],["2FQY_A_ADNA400_1","MEMBRANE LIPOPROTEIN TMPC","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"ASP H  86;PHE H  63;MET H  80;PHE H  69;GLY H  65","None","1.15A","2fqyA-2b4cH:undetectable","2fqyA-2b4cH:22.88"],["3HUO_A_PNNA302_0","CTX-M-9 EXTENDED-SPECTRUM BETA-LACTAMASE","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",4,"LEU H 189;GLY H 190;ALA H 125;PRO H 126","None","0.45A","3huoA-2b4cH:undetectable","3huoA-2b4cH:22.10"],["4QVN_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.90A","4qvnH-2b4cH:undetectable;4qvnI-2b4cH:undetectable","4qvnH-2b4cH:20.72;4qvnI-2b4cH:21.86"],["4QVN_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.90A","4qvnV-2b4cH:undetectable;4qvnW-2b4cH:undetectable","4qvnV-2b4cH:20.72;4qvnW-2b4cH:21.86"],["4QVP_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.87A","4qvpH-2b4cH:undetectable;4qvpI-2b4cH:undetectable","4qvpH-2b4cH:20.72;4qvpI-2b4cH:21.86"],["4QVP_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.87A","4qvpV-2b4cH:undetectable;4qvpW-2b4cH:undetectable","4qvpV-2b4cH:20.72;4qvpW-2b4cH:21.86"],["4QVQ_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.89A","4qvqH-2b4cH:undetectable;4qvqI-2b4cH:undetectable","4qvqH-2b4cH:20.72;4qvqI-2b4cH:21.86"],["4QVQ_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","4qvqV-2b4cH:undetectable;4qvqW-2b4cH:undetectable","4qvqV-2b4cH:20.72;4qvqW-2b4cH:21.86"],["4QVV_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.92A","4qvvH-2b4cH:undetectable","4qvvH-2b4cH:20.72"],["4QVV_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.92A","4qvvV-2b4cH:undetectable","4qvvV-2b4cH:20.72"],["4QVY_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.92A","4qvyH-2b4cH:undetectable","4qvyH-2b4cH:20.72"],["4QVY_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.93A","4qvyV-2b4cH:undetectable;4qvyW-2b4cH:undetectable","4qvyV-2b4cH:20.72;4qvyW-2b4cH:21.86"],["4QW0_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.91A","4qw0H-2b4cH:undetectable;4qw0I-2b4cH:undetectable","4qw0H-2b4cH:20.72;4qw0I-2b4cH:21.86"],["4QW0_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.91A","4qw0V-2b4cH:undetectable;4qw0W-2b4cH:undetectable","4qw0V-2b4cH:20.72;4qw0W-2b4cH:21.86"],["4QW1_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.92A","4qw1H-2b4cH:undetectable;4qw1I-2b4cH:undetectable","4qw1H-2b4cH:20.72;4qw1I-2b4cH:21.86"],["4QW1_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.92A","4qw1V-2b4cH:undetectable;4qw1W-2b4cH:undetectable","4qw1V-2b4cH:20.72;4qw1W-2b4cH:21.86"],["4QWU_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.92A","4qwuH-2b4cH:undetectable;4qwuI-2b4cH:undetectable","4qwuH-2b4cH:20.72;4qwuI-2b4cH:21.86"],["4QWU_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.93A","4qwuV-2b4cH:undetectable;4qwuW-2b4cH:undetectable","4qwuV-2b4cH:20.72;4qwuW-2b4cH:21.86"],["5ALC_L_TIQL1210_1","ANTI-TICAGRELOR FAB 72, HEAVY CHAIN;ANTI-TICAGRELOR FAB 72, LIGHT CHAIN","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"TRP H  47;ILE H  52;THR H  56;TYR H 100;ASP H  95","None","1.40A","5alcH-2b4cH:27.8","5alcH-2b4cH:80.93"],["5BXN_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.92A","5bxnH-2b4cH:undetectable;5bxnI-2b4cH:undetectable","5bxnH-2b4cH:20.72;5bxnI-2b4cH:21.86"],["5CZ7_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.89A","5cz7V-2b4cH:undetectable;5cz7W-2b4cH:undetectable","5cz7V-2b4cH:20.72;5cz7W-2b4cH:21.86"],["5D0X_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.90A","5d0xV-2b4cH:undetectable","5d0xV-2b4cH:20.72"],["5L5F_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.87A","5l5fH-2b4cH:undetectable;5l5fI-2b4cH:undetectable","5l5fH-2b4cH:20.72;5l5fI-2b4cH:21.86"],["5L5F_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","5l5fV-2b4cH:undetectable;5l5fW-2b4cH:undetectable","5l5fV-2b4cH:20.72;5l5fW-2b4cH:21.86"],["6HWD_H_BO2H301_0","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","1.05A","6hwdH-2b4cH:undetectable;6hwdI-2b4cH:undetectable","6hwdH-2b4cH:17.31;6hwdI-2b4cH:14.22"],["6HWD_V_BO2V301_0","PROTEASOME SUBUNIT BETA TYPE-2","2b4c","ANTI-HIV-1 GP120 IMMUNOGLOBULIN X5 HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","1.05A","6hwdV-2b4cH:undetectable","6hwdV-2b4cH:17.31"]]